Menu
Recruiting NCT06081998

Investigation of the Effects of Sleep Deprivation on Itch and Pain Sensitivity

No phase Interventional Histamine Cowhage Sleep Deprivation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Histamine, Cowhage.
Who it may be relevant to
Registry conditions: Histamine, Cowhage, Sleep Deprivation. Basic parameters: 18 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Denmark
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Investigation of the Effects of Sleep Provocations on Itch and Pain Sensitivity

Overview

In This experiment, the investigators would like to test following hypotheses regarding the influence of sleep deprivation on itch: * To investigate similarity and differences between itch and pain by comparing the effect of sleep deprivation in them. * To evaluate the inflammatory state induced by sleep fragmentation via the analysis of C-reactive protein (CRP) levels from blood samples. * To correlate the anxiety and depression scores (evaluated through questionnaires) with itch and pain sensitivity and evaluate how they are affected by sleep. In This experiment, the investigators would like to test following hypotheses regarding the influence of sleep fragmentation on itch: * To investigate similarity and differences between itch and pain by comparing the effect of sleep deprivation in them. * To evaluate the inflammatory state induced by sleep fragmentation via the analysis of C-reactive protein (CRP) levels from blood samples. * To correlate the anxiety and depression scores (evaluated through questionnaires) with itch and pain sensitivity and evaluate how they are affected by sleep deprivation.

Detailed description

Chronic itch affects approximately a fifth of the global population and is associated with substantial negative consequences for the affected individuals. Furthermore, there is a lack of efficient treatment options for chronic itch. Poor sleep is a common companion of itch and is often reported by patients with chronic itch. Poor sleep is often characterized by nightly awakenings and troubles falling asleep. This is a significant problem as poor sleep in general is associated with lowered quality of life. While previous research has already established the negative impact of itch on sleep, it is yet to be studied whether the opposite tendency might be true as well. Knowledge about patients with chronic pain has shown that poor sleep can increase the sensitivity to pain and inflammation, and this tendency can also be observed in healthy participants after experimental sleep provocations. Therefore, the investigators wish to investigate how sleep provocations affect markers of itch in healthy participants.

Interventions

  • Other Histamine
    Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds
  • Other Cowhage
    25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration

Primary outcome measures

  • Assessment of itch [Time frame: Day 1: 1 minute after every itch inductions]
  • Assessment of itch [Time frame: Day 2: 1 minute after every itch inductions]
  • Assessment of pain [Time frame: Day 1: 1 minute after every itch inductions]
  • Assessment of pain [Time frame: Day 2: 1 minute after every itch inductions]
Secondary outcome measures (12)
  • Microvascular reactivity [Time frame: Day 1: 10 minutes after every itch inductions]
  • Microvascular reactivity [Time frame: Day 2: 10 minutes after every itch inductions]
  • Touch Pleasantness (TP) [Time frame: Day 1: 10 minutes after every itch inductions]
  • Touch Pleasantness (TP) [Time frame: Day 2: 10 minutes after every itch inductions]
  • Mechanically evoked itch (MEI), intensity approach [Time frame: Day 1: 10 minutes after every itch inductions]
  • Mechanically evoked itch (MEI), intensity approach [Time frame: Day 2: 10 minutes after every itch inductions]
  • Mechanically evoked itch, spatial approach [Time frame: Day 1: 10 minutes after every itch inductions]
  • Mechanically evoked itch, spatial approach [Time frame: Day 2: 10 minutes after every itch inductions]
  • Mechanical Pain Thresholds (MPT) [Time frame: Day 1: 10 minutes after every itch inductions]
  • Mechanical Pain Thresholds (MPT) [Time frame: Day 2: 10 minutes after every itch inductions]
  • Mechanical Pain Sensitivity (MPS), intensity approach [Time frame: Day 1: 10 minutes after every itch inductions]
  • Mechanical Pain Sensitivity (MPS), intensity approach [Time frame: Day 2: 10 minutes after every itch inductions]

Eligibility criteria

Inclusion criteria

  • Healthy men and women
  • 18-60 years
  • Speak and understand English
  • Access to a smartphone during the experimental nights

Exclusion criteria

  • Pregnancy or lactation
  • Drug addiction defined as any use of cannabis, opioids, or other drugs
  • Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses (psychiatric diagnosis) that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia etc.)
  • Moles, wounds, scars, or tattoos in the area to be treated or tested
  • Current use of medications that may affect the trial such as antihistamines and pain killers.
  • Skin diseases
  • Consumption of alcohol or painkillers 24 hours before the study days and between these
  • Acute or chronic pain and itch
  • Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical studies)
  • Lack of ability to cooperate

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Basic science

Study locations

Denmark · 1 center
  • Aalborg University — Aalborg

Identifiers

NCT: NCT06081998 · N-20230028 2nd Experiment

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗